Maria Zimmermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Zimmermann has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Rosa-Neto
Montreal Neurological Institute, McGill University Health Centre, Montréal, Québec, Canada
2 shared publications - Peter Kunach
Center for Alzheimer’s and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 shared publications - Alessandra Cadete Martini
University of California, Irvine, Irvine, CA USA
1 shared publication - Arturo Aliaga
McGill University, Montreal, QC Canada
1 shared publication - Bruna Bellaver
Department of Psychiatry, School of Medicine, University of Pittsburgh, PA
1 shared publication - Cécile Tissot
Lawrence Berkeley National Laboratory
1 shared publication
Latest Publications
- Open Access
A Single-Cell Omics Technical Guide for Advancing Neuropsychiatric Research
Single-cell omics technology has advanced rapidly since its inception, offering increasing precision, resolution, and technical diversity to explore cell-specific molecular features in the human brain and neuropsychiatric disorders. While traditional bulk genomic analyses have provided valuable insights into the molecular processes of these disorders, single-cell omics allows for the investigation of cellular heterogeneity in the brain, which is crucial for dissecting underlying pathology. Neuropsychiatric disorders—such as dementia and depression—are complex and heterogenous brain disorders driven by intricate interactions of genetic and environmental factors. Methodological developments in single-cell omic technologies have enabled their application directly to human brain tissue for the study of neuropsychiatric disorders, yielding cell-specific insights in transcriptomics and epigenomics, with emerging findings in proteomics, metabolomics, multi-omics, and beyond. This review discusses different single-cell omic technologies, focusing on their application to postmortem human brain tissue, highlighting key findings from the use of these methods in neuropsychiatric disorders, and providing considerations for future implementation to elucidate the molecular landscape of brain changes associated with these conditions.
Open AccessA Single-Cell Omics Technical Guide for Advancing Neuropsychiatric Research
Single-cell omics technology has advanced rapidly since its inception, offering increasing precision, resolution, and technical diversity to explore cell-specific molecular features in the human brain and neuropsychiatric disorders. While traditional bulk genomic analyses have provided valuable insights into the molecular processes of these disorders, single-cell omics allows for the investigation of cellular heterogeneity in the brain, which is crucial for dissecting underlying pathology. Neuropsychiatric disorders—such as dementia and depression—are complex and heterogenous brain disorders driven by intricate interactions of genetic and environmental factors. Methodological developments in single-cell omic technologies have enabled their application directly to human brain tissue for the study of neuropsychiatric disorders, yielding cell-specific insights in transcriptomics and epigenomics, with emerging findings in proteomics, metabolomics, multi-omics, and beyond. This review discusses different single-cell omic technologies, focusing on their application to postmortem human brain tissue, highlighting key findings from the use of these methods in neuropsychiatric disorders, and providing considerations for future implementation to elucidate the molecular landscape of brain changes associated with these conditions.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Effect of alpha‐Synuclein on the binding of [18F]MK‐6240 and [18F]AV‐1451
Background: Binding in alpha‐synuclein containing brain regions have been described for both Flortaucipir ([18F]AV‐1451) and [18F]MK‐6240. Here we assessed whether alpha‐Synuclein constitutes a target for these tau imaging agents.Method: We used autoradiographic dot blot to validate specific and evaluate off‐target interactions of [18F]MK‐6240 and [18F]AV‐1451 using sarkosyl‐insoluble extracts from PSP, CBD, PiD, and AD cortical tissue which contain fibrillar forms of tau. Tissue concentrations of alpha‐Synuclein are orders of magnitude lower than NFTs leading us to use recombinant alpha‐Synuclein PFFs to evaluate potential off‐target interactions.Briefly, 1:100 dilutions of each preparation were incubated with 82 fmol of mass in a 30uL total volume. Samples were incubated for 90 minutes at 37°C. Reactions were terminated by pipetting the solution in triplicate onto a glass fiber filter held within a 96‐well dot‐blot aspiration device and the samples were immobilized. Unbound ligand was washed three times with ice cold PBS. The glass fiber filters were transferred to a cassette for exposure to autoradiographic film for 90 minutes and the activity in photostimulated luminescence units per mm2 was calculated using ImageJ software v.1.8.0.Result: Disintegrations were corrected for decay and normalized to cerebellar extracts for both ligands. [18F]MK‐6240 demonstrated high specificity, binding in AD extracts and AD extracts subject to trypsin treatment. [18F]AV‐1451 demonstrated similar binding in both native and trypsinized AD extracts, while also showing overlapping binding profiles in human alpha‐synuclein PFFs but not in mouse alpha‐synuclein PFFs.Conclusion: [18F]AV‐1451 binds to recombinant human alpha‐Synuclein PFFs as it does to native AD‐tau PHFs. Future experiments should assess patient derived alpha‐Synuclein aggregates as a potential off target binding to [18F]AV‐1451.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Open AccessEffect of alpha‐Synuclein on the binding of [18F]MK‐6240 and [18F]AV‐1451
Background: Binding in alpha‐synuclein containing brain regions have been described for both Flortaucipir ([18F]AV‐1451) and [18F]MK‐6240. Here we assessed whether alpha‐Synuclein constitutes a target for these tau imaging agents.Method: We used autoradiographic dot blot to validate specific and evaluate off‐target interactions of [18F]MK‐6240 and [18F]AV‐1451 using sarkosyl‐insoluble extracts from PSP, CBD, PiD, and AD cortical tissue which contain fibrillar forms of tau. Tissue concentrations of alpha‐Synuclein are orders of magnitude lower than NFTs leading us to use recombinant alpha‐Synuclein PFFs to evaluate potential off‐target interactions.Briefly, 1:100 dilutions of each preparation were incubated with 82 fmol of mass in a 30uL total volume. Samples were incubated for 90 minutes at 37°C. Reactions were terminated by pipetting the solution in triplicate onto a glass fiber filter held within a 96‐well dot‐blot aspiration device and the samples were immobilized. Unbound ligand was washed three times with ice cold PBS. The glass fiber filters were transferred to a cassette for exposure to autoradiographic film for 90 minutes and the activity in photostimulated luminescence units per mm2 was calculated using ImageJ software v.1.8.0.Result: Disintegrations were corrected for decay and normalized to cerebellar extracts for both ligands. [18F]MK‐6240 demonstrated high specificity, binding in AD extracts and AD extracts subject to trypsin treatment. [18F]AV‐1451 demonstrated similar binding in both native and trypsinized AD extracts, while also showing overlapping binding profiles in human alpha‐synuclein PFFs but not in mouse alpha‐synuclein PFFs.Conclusion: [18F]AV‐1451 binds to recombinant human alpha‐Synuclein PFFs as it does to native AD‐tau PHFs. Future experiments should assess patient derived alpha‐Synuclein aggregates as a potential off target binding to [18F]AV‐1451.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Cross‐species evidence of differential expression of S100A6 and SLC11A1 in the hippocampus of Alzheimer’s disease patients and mouse models
Background: The evaluation of similarities and differences between mouse models and human Alzheimer’s disease (AD) provides invaluable insights on disease pathophysiology. We compared hippocampal transcriptomic profiles of human late‐onset AD (LOAD) and early‐onset AD (EOAD) individuals with three mouse models (hAβ‐KI, APP/PS1 and 5xFAD) in an exploratory analysis. Afterwards, we validated the intersection of genes consistently altered in all groups using hippocampal tissue from APP/PS1 mice, and EOAD and LOAD patients.Methods: Five publicly available human AD/cognitively unimpaired (CU) transcriptomic profiles were collected from GEO (https://www.ncbi.nlm.nih.gov/geo/), merged and submitted to differential expression analysis (DEA) using R. APP/PS1 mouse model RNAseq data from two datasets (GSE149661 and GSE145907) were also collected. Finally, RNAseq data of 5xFAD and hAβ‐KI mouse models were obtained from AMP‐AD Knowledge Portal (https://www.synapse.org/) using synapser and synapserutils packages. All animal models were also submitted to DEA. Validation of selected genes was performed by qRT‐PCR. Target mRNA levels were normalized using β‐actin as a housekeeper gene. The results were expressed relative to wild‐type (WT) animals or CU controls using the 2−ΔΔCt method.Results: DEA identified 1164, 3261 and 1782 differentially expressed genes (DEGs) for the comparisons between hAβ‐KI, 5xFAD and APP/PS1 mutants versus WT controls, respectively. hAβ‐KI, APP/PS1, and 5xFAD mice exhibited more DEGs in common with LOAD than with EOAD patients. Interestingly, APP/PS1 and 5xFAD mice also presented more DEGs in common with LOAD than with EOAD patients. However, 5xFAD showed significantly higher DEGs intersection with EOAD than with hAβ‐KI and APP/PS1. Additionally, we identified S100A6, C1QB, SST, CD14, CD33, SLC11A1 and KCNK1 genes altered in both EOAD and LOAD as well as the three mouse models evaluated. qRT‐PCR analysis of these genes in EOAD, LOAD and APP/PS1 model revealed S100A6 and SLC11A1 consistently altered in human pathology and mouse model.Conclusion: Animal models seek to better simulate AD pathology, making the evaluation of their molecular overlap with human disease greatly important. S100A6, a calcium‐binding protein modulating several biological activities, and SLC11A1, a metal transporter associated with inflammatory processes, were consistently altered in our transcriptomics exploratory analyses and experimental validation, making them promising targets for further investigation.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S1)
Open AccessCross‐species evidence of differential expression of S100A6 and SLC11A1 in the hippocampus of Alzheimer’s disease patients and mouse models
Background: The evaluation of similarities and differences between mouse models and human Alzheimer’s disease (AD) provides invaluable insights on disease pathophysiology. We compared hippocampal transcriptomic profiles of human late‐onset AD (LOAD) and early‐onset AD (EOAD) individuals with three mouse models (hAβ‐KI, APP/PS1 and 5xFAD) in an exploratory analysis. Afterwards, we validated the intersection of genes consistently altered in all groups using hippocampal tissue from APP/PS1 mice, and EOAD and LOAD patients.Methods: Five publicly available human AD/cognitively unimpaired (CU) transcriptomic profiles were collected from GEO (https://www.ncbi.nlm.nih.gov/geo/), merged and submitted to differential expression analysis (DEA) using R. APP/PS1 mouse model RNAseq data from two datasets (GSE149661 and GSE145907) were also collected. Finally, RNAseq data of 5xFAD and hAβ‐KI mouse models were obtained from AMP‐AD Knowledge Portal (https://www.synapse.org/) using synapser and synapserutils packages. All animal models were also submitted to DEA. Validation of selected genes was performed by qRT‐PCR. Target mRNA levels were normalized using β‐actin as a housekeeper gene. The results were expressed relative to wild‐type (WT) animals or CU controls using the 2−ΔΔCt method.Results: DEA identified 1164, 3261 and 1782 differentially expressed genes (DEGs) for the comparisons between hAβ‐KI, 5xFAD and APP/PS1 mutants versus WT controls, respectively. hAβ‐KI, APP/PS1, and 5xFAD mice exhibited more DEGs in common with LOAD than with EOAD patients. Interestingly, APP/PS1 and 5xFAD mice also presented more DEGs in common with LOAD than with EOAD patients. However, 5xFAD showed significantly higher DEGs intersection with EOAD than with hAβ‐KI and APP/PS1. Additionally, we identified S100A6, C1QB, SST, CD14, CD33, SLC11A1 and KCNK1 genes altered in both EOAD and LOAD as well as the three mouse models evaluated. qRT‐PCR analysis of these genes in EOAD, LOAD and APP/PS1 model revealed S100A6 and SLC11A1 consistently altered in human pathology and mouse model.Conclusion: Animal models seek to better simulate AD pathology, making the evaluation of their molecular overlap with human disease greatly important. S100A6, a calcium‐binding protein modulating several biological activities, and SLC11A1, a metal transporter associated with inflammatory processes, were consistently altered in our transcriptomics exploratory analyses and experimental validation, making them promising targets for further investigation.